SG10201602434UA - Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus - Google Patents

Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus

Info

Publication number
SG10201602434UA
SG10201602434UA SG10201602434UA SG10201602434UA SG10201602434UA SG 10201602434U A SG10201602434U A SG 10201602434UA SG 10201602434U A SG10201602434U A SG 10201602434UA SG 10201602434U A SG10201602434U A SG 10201602434UA SG 10201602434U A SG10201602434U A SG 10201602434UA
Authority
SG
Singapore
Prior art keywords
rsv
vaccine
respiratory syncytial
syncytial virus
nanoparticle
Prior art date
Application number
SG10201602434UA
Other languages
English (en)
Inventor
Gale Smith
Yingyun Wu
Michael Massare
Ye Liu
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of SG10201602434UA publication Critical patent/SG10201602434UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201602434UA 2011-09-30 2012-09-27 Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus SG10201602434UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161542040P 2011-09-30 2011-09-30
US201161542721P 2011-10-03 2011-10-03
US201261611834P 2012-03-16 2012-03-16
US201261614286P 2012-03-22 2012-03-22

Publications (1)

Publication Number Publication Date
SG10201602434UA true SG10201602434UA (en) 2016-05-30

Family

ID=47996397

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201602434UA SG10201602434UA (en) 2011-09-30 2012-09-27 Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
SG11201400999VA SG11201400999VA (en) 2011-09-30 2012-09-27 Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201400999VA SG11201400999VA (en) 2011-09-30 2012-09-27 Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus

Country Status (14)

Country Link
US (4) US20130122032A1 (fr)
EP (1) EP2760469A4 (fr)
JP (1) JP2014530010A (fr)
KR (1) KR20140077169A (fr)
CN (2) CN105381457A (fr)
AU (1) AU2013201495B2 (fr)
BR (1) BR112014007616A2 (fr)
CA (1) CA2849471A1 (fr)
HK (1) HK1222125A1 (fr)
IL (1) IL231637A0 (fr)
MX (1) MX2014003777A (fr)
RU (1) RU2014117068A (fr)
SG (2) SG10201602434UA (fr)
WO (1) WO2013049342A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2370099T (pt) 2008-12-09 2016-07-14 Novavax Inc Proteínas f vsr modificadas e processos para a sua utilização
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
CA2909077A1 (fr) * 2013-04-08 2014-10-16 Stacie Lynn Lambert Composition de vaccin et son procede d'utilisation
JP2016533332A (ja) * 2013-09-24 2016-10-27 マサチューセッツ インスティテュート オブ テクノロジー 自己集合型ナノ粒子ワクチン
CN105087643A (zh) * 2014-04-16 2015-11-25 中国科学院上海巴斯德研究所 重组表达人呼吸道合胞病毒f1蛋白胞外区的方法及表达系统
US10100372B2 (en) 2014-06-18 2018-10-16 Georgia State University Research Foundation, Inc. Recombinant RSV reporter virus
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
WO2017040387A2 (fr) * 2015-08-31 2017-03-09 Technovax, Inc. Vaccin à base de pseudoparticules virales (vlp) contre le virus syncytial respiratoire humain (hrsv)
JP6975709B2 (ja) * 2015-09-02 2021-12-01 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. 安定化したウイルスクラスｉ融合タンパク質
EP3344291A4 (fr) 2015-09-03 2019-04-10 Novavax, Inc. Compositions vaccinales ayant une stabilité et une immunogénicité améliorées
CN106547635B (zh) 2015-09-18 2020-10-09 阿里巴巴集团控股有限公司 一种作业的操作重试方法和装置
PE20181354A1 (es) 2015-12-23 2018-08-22 Pfizer Mutantes de proteina f de rsv
CN106124767A (zh) * 2016-05-12 2016-11-16 广州瑞辉生物科技股份有限公司 呼吸道合胞病毒IgA抗体检测试纸条及其检测方法
EP3518967A4 (fr) 2016-10-03 2020-04-29 University of Massachusetts Procédés d'immunisation de sujets pré-immuns contre le virus respiratoire syncytial (vrs)
JP7149285B2 (ja) 2017-03-15 2022-10-06 ノババックス，インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物
JP7168938B2 (ja) 2017-04-04 2022-11-10 ユニヴァーシティ オブ ワシントン パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用
CN107050446B (zh) * 2017-04-19 2020-08-11 武汉博沃生物科技有限公司 经修饰的季节流感-rsv联合疫苗及其制备方法
WO2019063844A1 (fr) * 2017-09-29 2019-04-04 Universiteit Antwerpen Vaccination contre le virus respiratoire syncytial
CA3095216A1 (fr) 2018-02-28 2019-09-06 University Of Washington Vaccins a base de nanostructures auto-assemblables
AU2019238171A1 (en) 2018-03-19 2020-09-24 Novavax, Inc. Multivalent influenza nanoparticle vaccines
CN112969786A (zh) * 2018-10-12 2021-06-15 Sk生物科学株式会社 重组呼吸道合胞病毒活疫苗株及其制备方法
US20210401969A1 (en) * 2018-10-29 2021-12-30 Emory University Rsv virus-like particles and methods of use thereof
KR20200050264A (ko) * 2018-11-01 2020-05-11 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
EP3932424A4 (fr) * 2019-02-28 2022-10-12 KM Biologics Co., Ltd. Vaccin chimérique f/g contre le vrs
CN110229219B (zh) * 2019-06-21 2021-03-30 中国科学院武汉病毒研究所 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途
BR112022014830A2 (pt) * 2020-01-27 2022-09-27 Novavax Inc Formulações de vacina para coronavírus
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CN113855796B (zh) * 2021-07-30 2024-01-26 河北医科大学 卡介苗作为呼吸道合胞病毒灭活疫苗佐剂的应用
WO2023091766A2 (fr) * 2021-11-19 2023-05-25 RNAimmune, Inc. Compositions et méthodes pour vaccins contre le virus respiratoire syncytial (rsv) à base d'acide ribonucléique
WO2024050015A1 (fr) * 2022-09-01 2024-03-07 Novavax, Inc. Procédé en aval pour la purification de protéines virales avec un domaine de membrane hydrophobe destiné à être utilisé dans des compositions de vaccin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523657A1 (fr) * 2003-04-25 2005-03-31 Medimmune Vaccines, Inc. Systemes d'expression de virus parainfluenza recombinant et vaccins comportant des antigenes heterologues derives du metapneumovirus
WO2008114149A2 (fr) * 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Antigènes chimériques
DK2540312T3 (en) * 2007-07-19 2015-07-20 Novavax Inc Chimeric avian influenza VLPs
SI2222710T1 (sl) * 2007-12-24 2016-11-30 Id Biomedical Corporation Of Quebec Rekombinatni RSV antigeni
RU2010139478A (ru) * 2008-02-25 2012-05-20 Новавакс, Инк. (Us) Соединенные с сахарным стеклом вирусоподобные частицы (vlp)
KR101027159B1 (ko) * 2008-07-28 2011-04-05 뮤추얼아이피서비스(주) 타겟 영상 검출 장치 및 그 방법
PT2370099T (pt) * 2008-12-09 2016-07-14 Novavax Inc Proteínas f vsr modificadas e processos para a sua utilização
WO2010077712A1 (fr) * 2008-12-09 2010-07-08 Novavax, Inc. Particule de type viral du virus syncytial respiratoire bovin (vlps)

Also Published As

Publication number Publication date
SG11201400999VA (en) 2014-07-30
KR20140077169A (ko) 2014-06-23
EP2760469A4 (fr) 2015-03-18
WO2013049342A1 (fr) 2013-04-04
US20170319682A1 (en) 2017-11-09
CN105381457A (zh) 2016-03-09
HK1222125A1 (zh) 2017-06-23
MX2014003777A (es) 2015-05-15
RU2014117068A (ru) 2015-11-10
AU2013201495B2 (en) 2015-12-03
IL231637A0 (en) 2014-05-28
JP2014530010A (ja) 2014-11-17
EP2760469A1 (fr) 2014-08-06
AU2013201495A1 (en) 2013-04-18
CN104080476A (zh) 2014-10-01
US20150335730A1 (en) 2015-11-26
CA2849471A1 (fr) 2013-04-04
US20150306207A1 (en) 2015-10-29
US20130122032A1 (en) 2013-05-16
BR112014007616A2 (pt) 2017-04-04

Similar Documents

Publication Publication Date Title
HK1222125A1 (zh) 用於呼吸道合胞病毒的重組納米顆粒 疫苗
SG10201801431TA (en) Respiratory syncytial virus (rsv) vaccine
EP2780065A4 (fr) Système de masque nasal
GB2490507C (en) Respiratory mask
EP2776107A4 (fr) Ensemble échangeur pour traitement respiratoire
AP2014007993A0 (en) Vaccine against RSV
HK1202442A1 (en) Vaccines against hpv hpv
EP2806891A4 (fr) Vaccins basés sur le virus parainfluenza 5
HK1189884A1 (zh) 用於治療呼吸道合胞病毒感染的化合物
EP2716319A4 (fr) Masque laryngé
EP2753354A4 (fr) Vaccin sous-unitaire contre le virus respiratoire syncytial (rsv) en nano-émulsion
PL2755680T3 (pl) Preparaty szczepionkowe w postaci cząstek
ZA201405177B (en) Vesicular stomatitis virus for prime boost vaccines
IL221320A0 (en) Compounds for treating respiratory syncytial virus infections
HK1223644A1 (zh) 呼吸道合胞病毒半活疫苗
AU339730S (en) Respiratory mask
EP2678043A4 (fr) Vaccin recombinant contre le virus des oreillons
HK1223643A1 (zh) 呼吸道合胞病毒半活疫苗
HUP1100470A2 (en) Nanoparticle-based veterinary vaccine
EP2739629A4 (fr) Composés pour le traitement d'infections par le virus respiratoire syncytial
TWM432433U (en) Respiratory nasal tube
EP2752199A4 (fr) Vaccin muqueux contre rsv
HK1206272A1 (en) Vaccine against rsv rsv